ASCO Winners And Losers And Biogen's Discouraging Failure

It's a wrap. The annual American Society of Clinical Oncology (ASCO) conference has come to a close and that's got us wondering which companies deserve a gold star and which don't. The Motley Fool's Kristine Harjes and Todd Campbell weigh in on why Immunomedics (NASDAQ:IMMU) may have been ASCO's biggest loser and CAR-T drug developers Juno Therapeutics (NASDAQ:JUNO) and Kite Pharma (NASDAQ:KITE) its biggest winners. The two industry watchers also discuss AbbVie Inc.'s (NYSE:ABBV) Rova-T and whether the data AbbVie presented at ASCO last weekend justifies the $5.8 billion it paid to get its hands on that drug.